Steve Harr, See Remarks at Juno Therapeutics, Inc. (JUNO), sold 35,000 shares at $46.38 ($1.6M) on 2015-12-10, disclosed to the SEC on 2015-12-11.
Scheduled sale ($1.6M) by See Remarks under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $46.38 | 31,400 | $1.5M | 89.6% |
| 2 | $46.90 | 3,600 | $169K | 10.4% |
| Total | $46.43 avg | 35,000 | $1.6M | 100% |
| Filing → |
| JUNO | SELL | 2017-06-29 | $263K | — | Filing → |
| JUNO | SELL | 2016-06-13 | $2.6M | — | Filing → |
| JUNO | SELL | 2016-03-04 | $225K | — | Filing → |